Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
delolimogene mupadenorepvec · 1 trial · 1 indication
The AE reporting period begins upon receiving the first LOAd703 and/or atezolizumab treatment and continues until final visit at week 57
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Delolimogene mupadenorepvec plus atezolizumab |
| Name | Type | Description |
|---|---|---|
| delolimogene mupadenorepvec | GENETIC | LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL |
| atezolizumab | BIOLOGICAL | Atezolizumab is an anti-PD-L1 antibody |
Inclusion Criteria: 1. Pathological confirmation of melanoma. 2. A life expectancy of at least 3 months as per the investigator 3. Valid for Swedish patients: Patients has locally advanced melanoma or metastatic melanoma, but not eligible for complete resection of melanoma Valid for US patients: Pa...
Delolimogene mupadenorepvec is an investigational gene therapy being studied for the treatment of malignant melanoma, a type of skin cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Delolimogene mupadenorepvec is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol DTIL. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy.
Delolimogene mupadenorepvec is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The drug is being evaluated in early-stage clinical trials to assess its safety and potential efficacy.
Delolimogene mupadenorepvec has been studied in one clinical trial, identified as NCT04123470. This was a Phase I/II trial investigating the drug in combination with atezolizumab in patients with malignant melanoma. The trial has been completed and enrolled 24 participants.
Yes, delolimogene mupadenorepvec is also known as LOAd703. The clinical trial NCT04123470, which investigated the drug in malignant melanoma, used the name LOAd703 in its title. Both names refer to the same investigational gene therapy.